Phase 2 Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults between 18 and 75 years old who are being treated as outpatients (not currently hospitalised), of any gender
- People diagnosed with a specific type of high blood pressure in the lungs called pulmonary arterial hypertension (Group 1 PAH), confirmed by a procedure that measures blood pressure inside the heart and lungs (called a right heart catheterisation), with results meeting specific pressure thresholds
- People who are willing to give written consent to participate and are able to follow the study schedule and requirements
- People who have been on a stable, unchanged treatment for their pulmonary arterial hypertension for more than 90 days before joining the study
- Women who could become pregnant must have a negative pregnancy test before having an MRI scan as part of the study
Who may not be able to join:
- People with moderate to severe heart disease, including a weakened heart pump, significant thickening of the heart wall, or moderate to severe problems with heart valves
- People with a condition called chronic thromboembolic disease (long-term blood clots in the lung arteries)
- People whose lung blood pressure condition is caused by a parasitic infection called schistosomiasis
- People with currently active cancer
- People with sickle cell anaemia
- People who are pregnant or currently incarcerated
- People who are unable to have an MRI scan, for example due to metal fragments in the eye, severe claustrophobia, or being unable to lie flat
- People with medical or psychological conditions that, in the opinion of the study doctor, could create undue risk or interfere with the ability to follow the study requirements (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sudarshan Rajagopal, MD, PhD, Duke University
Phone: +1 919 660 2026
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Xenon MRI Red Blood Cell (RBC) percentage; Change in cardiogenic oscillation amplitudes
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.